INSM vs MRK
Insmed Incorporated vs Merck & Co. — AI-powered side-by-side comparison
INSM
Insmed Incorporated
56
Watch
VS
| Metric | INSM | MRK |
|---|
| AI Score |
56
|
70
|
| Price |
$132.61
|
$130.34
|
| P/E Ratio |
-32.26×
|
103.53×
|
| ROE |
-172.8%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
83.3%
|
75.4%
|
| Debt / Equity |
0.05×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
78.9
|
64.5
|
| Beta |
0.793
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INSM versus MRK.
MRK leads by 14 points.
MRK scores 70/100 (Buy) versus INSM at 56/100 (Watch).
INSM Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 185.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 50.2x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 185.8% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price-to-book of 50.2x prices in significant intangible value — Value
- ROE of only -111.3% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical